Abstract Search

ea0029p779 | Endocrine tumours and neoplasia | ICEECE2012

Sorafenib stops disease progression in the majority of patients with advanced differentiated thyroid cancer refractory to radioactive iodine.

Marotta V. , Ramundo V. , Del Prete M. , Marciello F. , Palmieri G. , Camera L. , Vitale M. , Colao A. , Faggiano A.

Differentiated thyroid cancers (DTC) have an excellent prognosis with a 10 year disease-related survival of 85%. However, about 5% of DTC patients develop an aggressive disease with distant metastasis and loss of radioactive iodine (RAI) avidity. An effective treatment is not available for these patients and survival rates are less than 15%. The MAP-kinase pathway is strikingly involved in the pathogenesis of DTC. This is why compounds striking the MAP-Kinase pathway may be us...

0 shares

ea0029p807 | Endocrine tumours and neoplasia | ICEECE2012

Long-acting somatostatin analogues are highly effective in men1 patients with early stage duodeno-pancreatic neuroendocrine tumors

Faggiano A. , Ramundo V. , Del Prete M. , Marotta V. , Marciello F. , Camera L. , Napolitano V. , De L. , Lombardi G. , Colao A.

Somatostatin analogues (SSA) represent a recognized therapeutic option in patients affected with functioning neuroendocrine tumors (NET). In non-functioning NET, SSA are reported to induce tumor stabilization in most of cases and objective response in <5%. NET associated to Multiple Endocrine Neoplasia type 1 (MEN1) are inherited tumors, generally located in the duodeno-pancreatic trait, characterized by well differentiated histotype, high expression of somatostatin recept...

0 shares

Endocrine Abstracts

Sorafenib stops disease progression in the majority of patients with advanced differentiated thyroid cancer refractory to radioactive iodine.

Long-acting somatostatin analogues are highly effective in men1 patients with early stage duodeno-pancreatic neuroendocrine tumors

BiosciAbstracts